Axol Bioscience

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

#ALS #Axol Bioscience #LifeArc #MND

Global initiative to tackle gaps in ALS/MND drug discovery 

A global initiative has launched to close the gap in ALS/MND drug discovery.  The ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience announced the launch of ‘Patient induced pluripotent stem cell (iPSC)-based Research to Improve Sporadic ALS Modelling’ (PRISM ALS), a collaborative effort to expand access to high-quality, patient-derived stem… Read More

#News

Diabetic eye disease
#Axol Bioscience #Ophthalmology #Stem cells

Axol to progress eye disease treatments with new acquisition 

Stem cell technologies company Axol Bioscience has acquired the ophthalmology business of Newcells Biotech.  The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services to biopharma, biotechnology and CRO customers across Europe and… Read More

#News

#Axol Bioscience #Cell lines #iPSC #Mergers and acquisitions #Phenocell #Pluripotent stem cells

iPSC technology provider Axol Bioscience acquires Phenocell

Axol Bioscience has fully acquired Phenocell, though financial terms of the agreement were not disclosed. The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services. Read More

#Business & Investment #News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Axol Bioscience #Neuroscience #Stem cells #StrataStem

A step closer to ‘clinical trial in a dish’ for Alzheimer’s  

Axol Bioscience has signed an exclusive agreement with StrataStem to access and commercialise its collection of Alzheimer’s Disease (AD) patient samples.   Harnessing its stem cell expertise, Axol will reprogramme these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a range… Read More

#News